Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2015

01-05-2015 | Research Article

RETRACTED ARTICLE: Evidence for involvement of steroid receptors and coactivators in neuroepithelial and meningothelial tumors

Authors: Mengying Liu, Kaiyuan Zhang, Yangang Zhao, Qiang Guo, Deyu Guo, Jiqiang Zhang

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

Steroid receptors such as androgen receptor (AR) and estrogen receptors (ER) ER-α and ER-β, and their receptor coactivators (steroid receptor coactivator, SRC) are widely localized in the brain. Although previous studies have investigated the expression of steroid receptors in brain tumors like astrocytoma, the studies on the expression of steroid receptors and SRCs in other brain tumors are lacking. Here, we investigated the expression of AR, ERs, and SRCs in neuroepithelial (medulloblastoma, ependymoma, oligodendroglioma) and meningothelial meningioma using tissue microarray immunohistochemistry. Compared to normal brain tissue, we found that the expression of SRC-1, SRC-3, and ER-α significantly decreased in meningothelial tumor and neuroepithelial tumor, suggesting that the SRC-1/SRC-3 levels may be regulated by ER-α. Moreover, the levels of AR strongly correlated to the levels of ER-β. Furthermore, correlation was also detected between SRC-3 and AR in neuroepithelial tumor, and between ER-α and ER-β in meningothelial tumor. In addition, the decreased ratio of SRC-1/SRC-3 was associated with an increase of ER-β in neuroepithelial tumor. These results indicate that expressions of different steroid receptors and activators may be tumor type dependent. While AR, ER-α, and ER-β may be involved in the pathogenesis of meningothelial tumor, SRCs/ER-β axis and SRC-3/AR axis may play a role in the pathogenesis of neuroepithelial tumor.
Literature
1.
Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav. 2013;63(2):301–7.CrossRefPubMed
2.
Baudry M, Bi X, Aguirre C. Progesterone-estrogen interactions in synaptic plasticity and neuroprotection. Neuroscience. 2013;239:280–94.CrossRefPubMed
3.
Zhang JQ, Cai WQ, Zhou DS, Su BY. Distribution and differences of estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain Res. 2002;935(1–2):73–80.CrossRefPubMed
4.
Fernandez-Guasti A, Kruijver FP, Fodor M, Swaab DF. Sex differences in the distribution of androgen receptors in the human hypothalamus. J Comp Neurol. 2000;425(3):422–35.CrossRefPubMed
5.
Kruijver FP, Fernandez-Guasti A, Fodor M, Kraan EM, Swaab DF. Sex differences in androgen receptors of the human mamillary bodies are related to endocrine status rather than to sexual orientation or transsexuality. J Clin Endocrinol Metab. 2001;86(2):818–27.CrossRefPubMed
6.
Liu F, Day M, Muniz LC, Bitran D, Arias R, Revilla-Sanchez R, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci. 2008;11(3):334–43.CrossRefPubMed
7.
Bean LA, Ianov L, Foster TC. Estrogen receptors, the hippocampus, and memory. Neuroscientist. 2014.
8.
Clipperton-Allen AE, Lee AW, Reyes A, Devidze N, Phan A, Pfaff DW, et al. Oxytocin, vasopressin and estrogen receptor gene expression in relation to social recognition in female mice. Physiol Behav. 2012;105(4):915–24.CrossRefPubMed
9.
Jones BA, Watson NV. Spatial memory performance in androgen insensitive male rats. Physiol Behav. 2005;85(2):135–41.CrossRefPubMed
10.
Cowppli-Bony A, Bouvier G, Rue M, Loiseau H, Vital A, Lebailly P, et al. Brain tumors and hormonal factors: review of the epidemiological literature. Cancer Causes Control. 2011;22(5):697–714.CrossRefPubMed
11.
12.
Carroll RS, Zhang J, Dashner K, Sar M, Black PM. Steroid hormone receptors in astrocytic neoplasms. Neurosurgery. 1995;37(3):496–503. discussion 503–494.CrossRefPubMed
13.
Kefalopoulou Z, Tzelepi V, Zolota V, Grivas PD, Christopoulos C, Kalofonos H, et al. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. J Neurooncol. 2012;106(1):23–31.CrossRefPubMed
14.
Schnegg JF, Gomez F, LeMarchand-Beraud T, de Tribolet N. Presence of sex steroid hormone receptors in meningioma tissue. Surg Neurol. 1981;15(6):415–8.CrossRefPubMed
15.
Tilzer LL, Plapp FV, Evans JP, Stone D, Alward K. Steroid receptor proteins in human meningiomas. Cancer. 1982;49(4):633–6.CrossRefPubMed
16.
Lee LS, Chi CW, Chang TJ, Chou MD, Liu HC, Liu TY. Steroid hormone receptors in meningiomas of Chinese patients. Neurosurgery. 1989;25(4):541–5.CrossRefPubMed
17.
Leaes CG, Meurer RT, Coutinho LB, Ferreira NP, Pereira-Lima JF, da Costa Oliveira M. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology. 2010;30(1):44–9.CrossRefPubMed
18.
Takei H, Buckleair LW, Powell SZ. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. Neuropathology. 2008;28(1):62–8.CrossRefPubMed
19.
Fakhrjou A, Meshkini A, Shadrvan S. Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. Pak J Biol Sci. 2012;15(11):530–5.CrossRefPubMed
20.
Mancuso M, Leonardi S, Ceccarelli M, Pasquali E, De Stefano I, Prisco MG, et al. Protective role of 17 beta-estradiol on medulloblastoma development in Patched 1 heterozygous mice. Int J Cancer. 2010;127(12):2749–57.CrossRefPubMed
21.
Mancuso M, Leonardi S, Giardullo P, Pasquali E, Borra F, Stefano ID, et al. The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways. Cancer Lett. 2011;308(2):197–202.CrossRefPubMed
22.
Belcher SM, Ma X, Le HH. Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology. 2009;150(3):1112–21.CrossRefPubMed
23.
Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048):1453–5.CrossRefPubMedPubMedCentral
24.
Batistatou A, Kyzas PA, Goussia A, Arkoumani E, Voulgaris S, Polyzoidis K, et al. Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol. 2006;77(1):17–23.CrossRefPubMed
25.
Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, Agnantis NJ. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol. 2004;130(7):405–10.CrossRefPubMed
26.
Onate SA, Tsai SY, Tsai MJ, O’Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270(5240):1354–7.CrossRefPubMed
27.
Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A. 1996;93(10):4948–52.CrossRefPubMedPubMedCentral
28.
Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A. 1997;94(16):8479–84.CrossRefPubMedPubMedCentral
29.
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277(5328):965–8.CrossRefPubMed
30.
Nishihara E, Yoshida-Komiya H, Chan CS, Liao L, Davis RL, O’Malley BW, et al. SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. J Neurosci. 2003;23(1):213–22.PubMed
31.
Ogawa H, Nishi M, Kawata M. Localization of nuclear coactivators p300 and steroid receptor coactivator 1 in the rat hippocampus. Brain Res. 2001;890(2):197–202.CrossRefPubMed
32.
Bian C, Zhu K, Guo Q, Xiong Y, Cai W, Zhang J. Sex differences and synchronous development of steroid receptor coactivator-1 and synaptic proteins in the hippocampus of postnatal female and male C57BL/6 mice. Steroids. 2012;77(1–2):149–56.CrossRefPubMed
33.
Zhang D, Guo Q, Bian C, Zhang J, Lin S, Su B. Alterations of steroid receptor coactivator-1 (SRC-1) immunoreactivities in specific brain regions of young and middle-aged female Sprague–Dawley rats. Brain Res. 2011;1382:88–97.CrossRefPubMed
34.
Bian C, Zhang D, Guo Q, Cai W, Zhang J. Localization and sex-difference of steroid receptor coactivator-1 immunoreactivities in the brain of adult female and male mice. Steroids. 2011;76(3):269–79.CrossRefPubMed
35.
Liu C, Zhang Y, Zhang K, Bian C, Zhao Y, Zhang J. Expression of estrogen receptors, androgen receptor and steroid receptor coactivator-3 is negatively correlated to the differentiation of astrocytic tumours. Cancer Epidemiol. 2014. doi:10.​1016/​ j.​canep.​2014.​1003.​1001.
36.
Wang H, Zhang D, Wu W, Zhang J, Guo D, Wang Q, et al. Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem. 2010;58(12):1121–7.CrossRefPubMedPubMedCentral
37.
Walsh CA, Qin L, Tien JC, Young LS, Xu J. The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci. 2012;8(4):470–85.CrossRefPubMedPubMedCentral
38.
Hernandez-Hernandez OT, Rodriguez-Dorantes M, Gonzalez-Arenas A, Camacho-Arroyo I. Progesterone and estradiol effects on SRC-1 and SRC-3 expression in human astrocytoma cell lines. Endocrine. 2010;37(1):194–200.CrossRefPubMed
39.
Gonzalez-Arenas A, Hansberg-Pastor V, Hernandez-Hernandez OT, Gonzalez-Garcia TK, Henderson-Villalpando J, Lemus-Hernandez D, et al. Estradiol increases cell growth in human astrocytoma cell lines through ERalpha activation and its interaction with SRC-1 and SRC-3 coactivators. Biochim Biophys Acta. 2012;1823(2):379–86.CrossRefPubMed
40.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRefPubMedPubMedCentral
41.
Liu C, Zhang Y, Zhang K, Bian C, Zhao Y, Zhang J. Expression of estrogen receptors, androgen receptor and steroid receptor coactivator-3 is negatively correlated to the differentiation of astrocytic tumors. Cancer Epidemiol. 2014;38(3):291–7.CrossRefPubMed
42.
Bao X, Cao L, Piao H, Xie L. Treatment-related secondary cancer in malignant meningiomas: a population-based study. J Cancer Res Clin Oncol. 2014;140(4):583–8.CrossRefPubMed
43.
Fujimoto M, Yoshino E, Hirakawa K, Fujimoto J, Tamaya T. Estrogen receptors in brain tumors. Clin Neuropharmacol. 1984;7(4):357–62.CrossRefPubMed
44.
Tao Y, Liang G, Li Z, Wang Y, Wu A, Wang H, et al. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse. Br J Neurosurg. 2012;26(5):700–4.CrossRefPubMed
45.
Baxter DS, Orrego A, Rosenfeld JV, Mathiesen T. An audit of immunohistochemical marker patterns in meningioma. J Clin Neurosci. 2014;21(3):421–6.CrossRefPubMed
46.
Pencovich N, Bot G, Lidar Z, Korn A, Wostrack M, Meyer B, Bydon M, Jallo G, Constantini S. Spinal ependymoma with regional metastasis at presentation. Acta Neurochir (Wien). 2014;Mar 8. [Epub ahead of print].
47.
Deval B, Rousset P, Bigenwald C, Nogales FF, Alexandre J. Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor. Obstet Gynecol. 2014;123(2 Pt 2 Suppl 2):488–91.CrossRefPubMed
48.
Stolnicu S, Furtado A, Sanches A, Nicolae A, Preda O, Hincu M, et al. Ovarian ependymomas of extra-axial type or central immunophenotypes. Hum Pathol. 2011;42(3):403–8.CrossRefPubMed
49.
Matsuyama A, Hisaoka M, Yamamoto I, Toyoshima S, Hashimoto H. Extraspinal ependymoma of the broad ligament. Pathol Int. 2010;60(3):241–4.CrossRefPubMed
50.
Concolino G, Liccardo G, Conti C, Panfili C, Giuffre R. Hormones and tumours in central nervous system (CNS): steroid receptors in primary spinal cord tumours. Neurol Res. 1984;6(3):121–6.CrossRefPubMed
51.
Favaro R, Appolloni I, Pellegatta S, Sanga AB, Pagella P, Gambini E, Pisati F, Ottolenghi S, Foti M, Finocchiaro G, Malatesta P, Nicolis SK. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res. 2014.
52.
Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol. 2001;60(8):808–16.CrossRefPubMed
53.
Ramachandran C, Khatib Z, Petkarou A, Fort J, Fonseca HB, Melnick SJ, et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol. 2004;67(1–2):19–28.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Evidence for involvement of steroid receptors and coactivators in neuroepithelial and meningothelial tumors
Authors
Mengying Liu
Kaiyuan Zhang
Yangang Zhao
Qiang Guo
Deyu Guo
Jiqiang Zhang
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2954-1

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue

Research Commentary

Letter regarding Li JS et al. entitled “ERCC polymorphisms and prognosis of patients with osteosarcoma”

Research Article

Construction of a plasmid for overexpression of human circadian gene period2 and its biological activity in osteosarcoma cells

Research Article

HIF-1α (1772C>T) polymorphism as marker for breast cancer development

Research Article

Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma

Research Article

MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2

Research Article

HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits